BRAF and neoplasm: Biomarkers such as BRAF V600E mutations, NTRK and RET fusions, high tumor mutational burden (TMB-H), and dMMR/MSI-H have not only expanded the armamentarium of targeted and immunotherapeutic agents but have also facilitated more personalized care with the potential for improved survival and quality of life.